Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 3:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 8,274 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Risk Clear all

Conditions: Leukemia, Myeloid, Myelodysplastic Syndromes
Interventions: clofarabine, Ara-C; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 50 Years to 74 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Disease
Interventions: Expanded Food and Nutrition Education Program (EFNEP); Behavioral
Lead sponsor: South Dakota State University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Fort Collins, Colorado • Gainesville, Florida • College Park, Maryland + 1 more

Conditions: Postoperative Nausea and Vomiting
Interventions: transdermal nicotine patch, placebo patch; Drug
Lead sponsor: Ochsner Health System; Other
Eligibility: 18 Years to 65 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Psychiatric Disorder
Interventions: Pharmacogentic Analysis; Genetic
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: AML, Adult, MDS, Relapse/Recurrence, Refractory Acute Myeloid Leukemia
Interventions: BST-236; Drug
Lead sponsor: BioSight Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Shreveport, Louisiana • Houston, Texas • Charlottesville, Virginia + 1 more

Conditions: Breast Cancer
Interventions: Elacestrant, Anastrozole, Letrozole, Exemestane, Tamoxifen; Drug
Lead sponsor: Stemline Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4,556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 170
States / cities: Daphne, Alabama • Chandler, Arizona • Gilbert, Arizona + 134 more

Conditions: Low-Risk, Early Stage Breast Cancer
Interventions: Cryoablation; Device
Lead sponsor: IceCure Medical Ltd.; Industry
Eligibility: 70 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 3
States / cities: Glendale, California • Portland, Oregon • Germantown, Tennessee

Conditions: Risk Reduction
Interventions: Trivalent Invasive Salmonella Disease Vaccine (6.25 µg), Trivalent Invasive Salmonella Disease Vaccine (12 µg), Trivalent Invasive Salmonella Disease Vaccine (25 µg), Trivalent Invasive Salmonella Disease Vaccine (highest, well-tolerated dose among Cohorts A-C), Placebo; Biological · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 45 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Mental Disorders
Interventions: Testing (MRS, US, DEXA, blood tests); Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 6 Years to 18 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Graft Versus Host Disease, Acute
Interventions: CYP-001: Cymerus induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs), Placebo, Corticosteroids; Biological · Drug
Lead sponsor: Cynata Therapeutics Limited; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 13
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Jacksonville, Florida + 9 more

Conditions: Mastitis, Staphylococcus Aureus, Staphylococcal Infections
Interventions: Not listed
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 557 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Prostate Cancer
Interventions: questionnaire administration, quality-of-life assessment, brachytherapy; Other · Procedure · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertriglyceridemia
Interventions: Docosahexenoic acid (DHA), Olive oil; Dietary Supplement
Lead sponsor: USDA, Western Human Nutrition Research Center; Federal
Eligibility: 39 Years to 66 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Davis, California

Conditions: Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
Interventions: Ibrutinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cardiovascular (CV) Risk
Interventions: Neqpiaput linruugut (Our Food is Medicine); Behavioral
Lead sponsor: University of Alaska Fairbanks; Other
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Fairbanks, Alaska

Conditions: Soft Tissue Sarcoma
Interventions: External Beam Radiation Therapy (RT), Autologous Dendritic Cells; Procedure · Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 3
States / cities: Gainesville, Florida • Jacksonville, Florida • Tampa, Florida

Conditions: Substance Use
Interventions: Brief motivational intervention; Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Leukemia
Interventions: sargramostim, busulfan, cyclophosphamide, cytarabine, gemtuzumab ozogamicin (GO), Daunorubicin, Autologous HCT, Allogeneic HCT; Biological · Drug · Procedure
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 16 Years to 60 Years
Enrollment: 657 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2019
U.S. locations: 98
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Aurora, Colorado + 69 more

Conditions: Substance Use Disorders, Risk Behavior, Psychiatric Disorders, Family Dysfunction
Interventions: Family Therapy based on Structural Family Therapy, Group Therapy, Psychoeducational Sessions, Individual Adolescent Therapy Sessions; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 14 Years to 17 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Cancer
Interventions: cytomegalovirus IE-1-specific cytotoxic T lymphocytes, cytomegalovirus pp65-specific cytotoxic T lymphocytes, therapeutic allogeneic lymphocytes, polymerase chain reaction, flow cytometry, immunological diagnostic method, laboratory biomarker analysis; Biological · Genetic · Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 2 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: HIV/AIDS
Interventions: Seek and Test Phase, Treat and Retain Phase; Behavioral
Lead sponsor: New York University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Lower Back Injury
Interventions: Lumbar ext. high intensity progressive resistance exercise, Low intensity core stabilization exercise; Other
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 35 Years
Enrollment: 582 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Tampa, Florida • Fort Sam Houston, Texas

Conditions: Interval Growth Ultrasound
Interventions: Ultrasound; Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 228 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Kidney Stones
Interventions: chlorthalidone, Hydrochlorothiazide; Drug
Lead sponsor: VA New York Harbor Healthcare System; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

Biomarker Cost-Benefit Analysis of EFNEP

Transdermal Nicotine in Female Patients at High Risk for Post Operative Nausea and/or Vomiting (PONV)

Using Pharmacogenetics to Identify Patients With Polypharmacy at Risk of Medication Adverse Effects

Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Post-Marketing Study for Early-Stage Low-Risk Breast Cancer Treatment Using ProSense® Cryoablation (ChoICE Trial)

Salmonella Conjugates CVD 1000: Study of Responses to Vaccination With Trivalent Invasive Salmonella Disease Vaccine

Measurement of Cardiometabolic Risk in Antipsychotic-Treated Children

A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD

Staphylococcus Aureus Carrier Status in Breastfeeding Mothers and Infants and the Risk of Lactation Mastitis

Internal Radiation Therapy in Treating Patients With Prostate Cancer

Docosahexenoic Acid (DHA) Supplementation and Cardiovascular Disease in Men With High Triglycerides

Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)

Neqpiaput Iinruugut (Our Food Is Medicine): A Tribally Driven Food Sovereignty Intervention to Reduce Heart Disease Risk in Alaska Native Adults

Radiation Therapy and Intratumoral Autologous Dendritic Cells in Soft Tissue Sarcomas (STS)

Brief Intervention in At-Risk First-time Mothers

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia

Culturally Informed Family Based Treatment of Adolescents: A Randomized Trial

Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections

Hybrid STTR Intervention for Heterosexuals: Anonymous Testing and Confidential Care Linkage

Reduction of Risk for Low Back Injury in Theater of Operations

Timing of Serial Ultrasounds

Night Time Use of Thiazide Diuretics for Improved Reduction in Stone Risk in Stone Formers With Elevated Urine Calcium